Nezutatug

尼组妥塔单抗

Report date: 2026/05/26 16:16:28

Base Information

Drug NameNezutatug
Drug Alias Nameanti-HER3 antibodyHMBD-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaUnited KingdomMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHummingbird Bioscience
China Registration ClassN/A

Develop Information

Active CompaniesHummingbird BioscienceHarvest Integrated Research Organization
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[16] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A